A study investigating the effectiveness of HPV vaccines has revealed that a single dose is as successful at preventing cervical cancer as multiple doses.
List view / Grid view
Filter the results
Analysis of the designs of Phase II and III efficacy trials for HPV vaccines suggest they overstated their effectiveness against cervical cancer, according to researchers.
A recent report has predicted that the cervical cancer vaccine market will increase to $6bn by the end of the forecast period.
Roche’s medicine Avastin plus chemotherapy improved survival in women with advanced cervical cancer, compared to chemotherapy alone
2 June 2013 | By Roche
Results of study GOG240...